Evidence map›Paper›PMID 42443900›Full record

ArticleCell communication and signaling : CCS2026

Dual targeting of interlocked PTK2B and MAPK signaling triggers synergistic ferroptosis via autophagic flux disruption in BRAF

Min Wang, Chengyan Xu, Shanshan Xie, Jichen Jin, Pengqi Zhang, Jiyong Liu, Cheng Wu, Yongmei Xi, Xiaohang Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Min Wang *Department of Neurosurgery, Center for Genetic Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China. wangminnnn@zju.edu.cn.
Chengyan Xu *Department of Neurosurgery, The Children's Hospital Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, 310058, China.
Shanshan Xie *Department of Neurosurgery, Center for Genetic Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Jichen JinDepartment of Neurosurgery, Center for Genetic Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Pengqi ZhangDepartment of Neurosurgery, Center for Genetic Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Jiyong LiuSino-French Hoffmann Institute, Guangzhou Medical University, Xinzao Road 1, Guangzhou , 511436, China.
Cheng WuDepartment of Neurosurgery, Center for Genetic Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Yongmei XiDepartment of Neurosurgery, Center for Genetic Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China. xyyongm@zju.edu.cn.
Xiaohang YangDepartment of Neurosurgery, Center for Genetic Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China. xhyang@zju.edu.cn.

Funding

International institutes of medicine, Zhejiang University Startup Funding (Q23019)
6 · The paper itself

Abstract

backgroundBRAF

methodsUsing patient gene expression profiles, immunohistochemistry on glioma samples, glioma cell lines, and a Drosophila glioma model, we identified Protein Tyrosine Kinase 2 Beta (PTK2B) as a druggable vulnerability in BRAF

resultsPTK2B and its Drosophila orthologue Focal adhesion kinase (Fak) are highly expressed in BRAF

conclusionsOur findings establish PTK2B as a critical regulator and co-targetable vulnerability in BRAF

Indexed as

AutophagyBrain NeoplasmsFocal Adhesion Kinase 2GliomaMAP Kinase Signaling SystemProto-Oncogene Proteins B-rafAnimalsCell Line, TumorCell ProliferationHumansMutationBRAF protein, humanFocal Adhesion Kinase 2Proto-Oncogene Proteins B-rafPTK2B protein, humanAutophagic flux disruptionBRAF V600E gliomaFerroptosisMAPK signalingPTK2B

Identifiers

PMID42443900
PMCPMC13629129

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.